Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,299 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06000527Recruiting
A French study on juvenile recurrent respiratory papillomatosis
This study is creating a national group of patients with juvenile recurrent respiratory papillomatosis, a condition causing wart-like growths in the airway. It aims to learn more about the disease and improve care.
ParisAges Any age - NCT06050148RecruitingPhase 2/Phase 3
Fecal Transplant to Prevent Repeat Urinary Tract Infections
This trial tests whether a fecal microbiota transplant (a procedure that transfers healthy bacteria from a donor's stool into your gut) can help prevent repeat urinary tract infections in women who have frequent infections.
HelsinkiAges 18–90 - NCT05832827RecruitingPhase 2
First treatment combo for thymic cancer using pembrolizumab plus drugs
This Phase 2 study tests a first (initial) treatment combination of pembrolizumab with three other drugs (carboplatin, paclitaxel, and lenvatinib) for advanced or recurrent thymic carcinoma. It aims to shrink tumors and improve control of the cancer when standard chemotherapy has not yet been tried for your situation.
Chūō, TokyoAges 18 years+ - NCT05916261RecruitingEarly Phase 1
Personalized pancreatic cancer vaccines with pembrolizumab
This early-phase trial tests a personalized cancer vaccine made from your tumor, along with pembrolizumab, to help the immune system attack advanced pancreatic cancer. It may be an option if your cancer has specific immune “targets” and if you meet several health, lab, and infection requirements.
Qionghai, HainanAges 18 years+ - NCT06118762RecruitingPhase 4
Study of fruquintinib plus raltitrexed for advanced colorectal cancer
This trial tests two drugs, fruquintinib and raltitrexed, for people with metastatic colorectal cancer that has stopped responding to or is no longer tolerable after standard treatments like fluorouracil, oxaliplatin, and irinotecan. The goal is to see if this combination can help shrink or control the cancer.
Nanchang, JiangxiAges 18 years+ - NCT05444270Recruiting
Radiation and medicine for recurrent ovarian cancer
This trial studies a “salvage” (next-line) cancer treatment for recurrent epithelial ovarian cancer, with or without a focused type of radiation. It may help by shrinking or controlling limited spots of cancer that have come back after prior standard treatment.
SeoulAges 19 years+ - NCT05451784RecruitingPhase 1/Phase 2
PD-1 TIL therapy for advanced triple-negative breast cancer
This study tests an immune-cell treatment made from your tumor tissue. It aims to help people with advanced or metastatic triple-negative breast cancer by collecting PD-1–positive immune cells and giving them back after treatment.
BarcelonaAges 18 years+ - NCT06152757RecruitingEarly Phase 1
Cell therapy for advanced gastrointestinal cancers
This trial tests a new type of cell therapy (BGT007H cells) for people with advanced gastrointestinal cancers that have not responded to at least two standard treatments. The therapy uses your own immune cells that are modified to target and attack the cancer.
Zhengzhou, HenanAges 18 years+ - NCT05930613RecruitingPhase 3
Certolizumab for repeated embryo transfer pregnancy failure
This Phase 3 study tests certolizumab to help people with repeated embryo transfer failures achieve a clinical pregnancy. It may be an option if your infertility has no known cause and you meet the other study checks.
ParisAges 18–40 - NCT06168032Recruiting
COVID-19 vaccine for lung cancer patients
This trial is testing how well the COVID-19 vaccine works for people with lung cancer to prevent another infection. It also looks at certain biomarkers in your blood that might help predict your body's immune response.
BeijingAges 18 years+ - NCT04894370RecruitingPhase 2
Trial tests immunotherapy plus chemotherapy and radiation for anal cancer
This Phase 2 trial studies a combination of immunotherapy (spartalizumab), chemotherapy (mDCF includes docetaxel), and radiation to treat metastatic or returning anal squamous cell cancer. It may help shrink tumors and improve outcomes compared with standard approaches, but eligibility is strict to keep participants safe.
BesançonAges 18 years+ - NCT06185621Recruiting
Aspirin to prevent recurrent pancreatitis
This trial tests if taking aspirin daily can prevent repeated attacks of acute pancreatitis. It's for people who have had at least two episodes of pancreatitis in the past year that were not caused by a medical procedure.
Xi'an, ShaanxiAges 14–80 - NCT06220552RecruitingPhase 2
Low-dose radiation plus immunotherapy for recurrent glioblastoma
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
Zhuhai, GuangdongAges 18 years+ - NCT06242067RecruitingPhase 2
Second-line treatment for advanced colorectal cancer
This trial tests a new treatment for people with advanced colorectal cancer that has spread or come back after initial chemotherapy. It is for those who have already received standard first-line therapy and are now looking for a second treatment option.
Jinan, ShandongAges 18–75 - NCT06230549Recruiting
Adaptive radiotherapy for gynecological tumors
This trial tests a personalized radiation therapy approach for gynecological tumors. It aims to improve treatment by adapting the radiation plan based on changes in the tumor and nearby organs during your therapy course.
Essen, Germany / NRWAges 18 years+ - NCT05988814RecruitingPhase 2
FOLFIRINOX3 for advanced pancreatic cancer
This trial tests a stronger version of FOLFIRINOX chemotherapy for people with pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body. It aims to see if the new dosing schedule works better and is safe.
DijonAges 18 years+ - NCT06220188RecruitingPhase 2
PSMA therapy for prostate cancer that has come back
This trial tests a targeted radiation therapy (PSMA-RLT) for men whose prostate cancer has returned after initial treatment, shown only by rising PSA levels. It aims to control the cancer without using hormone therapy.
ViennaAges 18–80 - NCT05007132RecruitingPhase 2
First-line metastatic colon or rectal cancer study with targeted drugs
This Phase 2 trial compares two treatment combinations as a first treatment for metastatic (spread) colon or rectal cancer. It looks to see whether one combo works better or is safer than the other.
BerlinAges 18 years+ - NCT06223841RecruitingPhase 1/Phase 2
Testing IAP0971 for advanced solid tumors and lung cancer
This trial tests a new drug, IAP0971, in patients with advanced solid tumors or a specific type of lung cancer (non-small cell lung cancer, or NSCLC) that has high PD-L1 levels. It aims to see if the drug can help when standard treatments have stopped working or are not an option.
Beijing, Beijing MunicipalityAges 18–75 - NCT07860528Recruiting
High-dose brachytherapy for prostate cancer that has returned
This trial tests a type of radiation therapy called high-dose-rate brachytherapy, which is given to men whose prostate cancer has come back after their first treatment. It aims to control the cancer while keeping side effects low.
Benidorm, AlicanteAges 18 years+ - NCT06283927Recruiting
Surgery vs. medical care for recurrent glioblastoma
This trial compares surgery to the best non-surgical treatment for people whose glioblastoma has come back. The goal is to see which approach helps people live longer with a better quality of life.
San Francisco, CaliforniaAges 18–90 - NCT06305832RecruitingPhase 2
Salvage radiation plus hormone therapy with or without rezvilutamide for rising PSA
This trial tests whether adding a new oral hormone blocker (rezvilutamide) to standard salvage radiation and hormone therapy can better control prostate cancer that has come back (rising PSA) after surgery.
Nanjing, JiangsuAges 40 years+ - NCT06329999Recruiting
CMGV for recurrent AML and high-risk MDS
This study tests a new treatment called CMGV for adults whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) has returned or is not improving. It is for people who may be older or have had other blood disorders.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04660760RecruitingPhase 2
Comparing two treatments for advanced stomach cancer after first treatment
This study tests two different treatment options for advanced stomach or gastroesophageal junction cancer that has grown after earlier chemotherapy. One option combines a targeted therapy (ramucirumab) with a chemotherapy pill (trifluridine/tipiracil), and the other is a standard chemotherapy drug (paclitaxel). The goal is to see which approach works better for people whose cancer has progressed, with the hope of improving outcomes.
Birmingham, AlabamaAges 18 years+
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,299 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.